{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:51:27Z","timestamp":1792785087142,"version":"4.5.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":86,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Amsterdam UMC (LSH-TKI project) and Health~Holland","id":[{"id":"https:\/\/ror.org\/05grdyy37","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"DOI":"10.1038\/s42003-026-10662-6","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T17:34:24Z","timestamp":1783964064000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Anti-capsid nanobodies function as HIV-1 capsid inhibitors by intracellular capsid degradation"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3781-8223","authenticated-orcid":false,"given":"Florence M.","family":"Stel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1482-2648","authenticated-orcid":false,"given":"Charlotte E. J.","family":"Verkuijlen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther M.","family":"Zijlstra-Willems","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian","family":"Dekkers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raimond","family":"Heukers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9429-7754","authenticated-orcid":false,"given":"Neeltje A.","family":"Kootstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5710-2839","authenticated-orcid":false,"given":"Teunis B. H.","family":"Geijtenbeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"key":"10662_CR1","doi-asserted-by":"publisher","DOI":"10.1177\/13596535231201162","volume":"28","author":"A Carr","year":"2023","unstructured":"Carr, A., Mackie, N. E., Paredes, R. & Ruxrungtham, K. HIV drug resistance in the era of contemporary antiretroviral therapy: a clinical perspective. Antivir. Ther. 28, 13596535231201162 (2023).","journal-title":"Antivir. Ther."},{"key":"10662_CR2","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.antiviral.2013.01.007","volume":"98","author":"L Menendez-Arias","year":"2013","unstructured":"Menendez-Arias, L. Molecular basis of human immunodeficiency virus type 1 drug resistance: overview and recent developments. Antivir. Res. 98, 93\u2013120 (2013).","journal-title":"Antivir. Res."},{"key":"10662_CR3","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1093\/cid\/ciu701","volume":"59","author":"J Schouten","year":"2014","unstructured":"Schouten, J. et al. Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study. Clin. Infect. Dis. 59, 1787\u20131797 (2014).","journal-title":"Clin. Infect. Dis."},{"key":"10662_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s12981-024-00667-8","volume":"21","author":"LB de Camargo Vicioli","year":"2024","unstructured":"de Camargo Vicioli, L. B. & de Souza, E. Brief communication: comorbidities and aging in people living with HIV. AIDS Res. Ther. 21, 77 (2024).","journal-title":"AIDS Res. Ther."},{"key":"10662_CR5","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1089\/aid.2020.0216","volume":"37","author":"H Stires","year":"2021","unstructured":"Stires, H. et al. Weight gain and related comorbidities following antiretroviral initiation in the 2000s: a systematic literature review. AIDS Res. Hum. Retroviruses 37, 834\u2013841 (2021).","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"10662_CR6","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1097\/COH.0000000000000472","volume":"13","author":"SK Carnes","year":"2018","unstructured":"Carnes, S. K., Sheehan, J. H. & Aiken, C. Inhibitors of the HIV-1 capsid, a target of opportunity. Curr. Opin. HIV AIDS 13, 359\u2013365 (2018).","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10662_CR7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1097\/COH.0000000000000713","volume":"17","author":"H Dvory-Sobol","year":"2022","unstructured":"Dvory-Sobol, H., Shaik, N., Callebaut, C. & Rhee, M. S. Lenacapavir: a first-in-class HIV-1 capsid inhibitor. Curr. Opin. HIV AIDS 17, 15\u201321 (2022).","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10662_CR8","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/nrmicro3503","volume":"13","author":"EM Campbell","year":"2015","unstructured":"Campbell, E. M. & Hope, T. J. HIV-1 capsid: the multifaceted key player in HIV-1 infection. Nat. Rev. Microbiol. 13, 471\u2013483 (2015).","journal-title":"Nat. Rev. Microbiol."},{"key":"10662_CR9","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.tim.2017.04.004","volume":"25","author":"M Yamashita","year":"2017","unstructured":"Yamashita, M. & Engelman, A. N. Capsid-dependent host factors in HIV-1 infection. Trends Microbiol. 25, 741\u2013755 (2017).","journal-title":"Trends Microbiol."},{"key":"10662_CR10","doi-asserted-by":"publisher","unstructured":"Christensen, D. E., Ganser-Pornillos, B. K., Johnson, J. S., Pornillos, O. & Sundquist, W. I. Reconstitution and visualization of HIV-1 capsid-dependent replication and integration in vitro. Science https:\/\/doi.org\/10.1126\/science.abc8420 (2020).","DOI":"10.1126\/science.abc8420"},{"key":"10662_CR11","doi-asserted-by":"publisher","first-page":"5667","DOI":"10.1128\/JVI.76.11.5667-5677.2002","volume":"76","author":"BM Forshey","year":"2002","unstructured":"Forshey, B. M., von Schwedler, U., Sundquist, W. I. & Aiken, C. Formation of a human immunodeficiency virus type 1 core of optimal stability is crucial for viral replication. J. Virol. 76, 5667\u20135677 (2002).","journal-title":"J. Virol."},{"key":"10662_CR12","doi-asserted-by":"publisher","first-page":"5439","DOI":"10.1128\/JVI.77.9.5439-5450.2003","volume":"77","author":"UK von Schwedler","year":"2003","unstructured":"von Schwedler, U. K., Stray, K. M., Garrus, J. E. & Sundquist, W. I. Functional surfaces of the human immunodeficiency virus type 1 capsid protein. J. Virol. 77, 5439\u20135450 (2003).","journal-title":"J. Virol."},{"key":"10662_CR13","doi-asserted-by":"publisher","first-page":"e1003461","DOI":"10.1371\/journal.ppat.1003461","volume":"9","author":"SJ Rihn","year":"2013","unstructured":"Rihn, S. J. et al. Extreme genetic fragility of the HIV-1 capsid. PLoS Pathog. 9, e1003461 (2013).","journal-title":"PLoS Pathog."},{"key":"10662_CR14","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1056\/NEJMoa2115542","volume":"386","author":"S Segal-Maurer","year":"2022","unstructured":"Segal-Maurer, S. et al. Capsid inhibition with lenacapavir in multidrug-resistant HIV-1 Infection. N. Engl. J. Med. 386, 1793\u20131803 (2022).","journal-title":"N. Engl. J. Med."},{"key":"10662_CR15","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/s41586-020-2443-1","volume":"584","author":"JO Link","year":"2020","unstructured":"Link, J. O. et al. Clinical targeting of HIV capsid protein with a long-acting small molecule. Nature 584, 614\u2013618 (2020).","journal-title":"Nature"},{"key":"10662_CR16","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(25)00405-2","volume":"405","author":"V Jogiraju","year":"2025","unstructured":"Jogiraju, V. et al. Pharmacokinetics and safety of once-yearly lenacapavir: a phase 1, open-label study. Lancet 405, 1147\u20131154 (2025).","journal-title":"Lancet"},{"key":"10662_CR17","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1126\/science.abb4808","volume":"370","author":"SM Bester","year":"2020","unstructured":"Bester, S. M. et al. Structural and mechanistic bases for a potent HIV-1 capsid inhibitor. Science 370, 360\u2013364 (2020).","journal-title":"Science"},{"key":"10662_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2021.103593","volume":"25","author":"A Selyutina","year":"2022","unstructured":"Selyutina, A. et al. GS-CA1 and lenacapavir stabilize the HIV-1 core and modulate the core interaction with cellular factors. iScience 25, 103593 (2022).","journal-title":"iScience"},{"key":"10662_CR19","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1093\/jac\/dkab503","volume":"77","author":"N Margot","year":"2022","unstructured":"Margot, N. et al. Phenotypic resistance to lenacapavir and monotherapy efficacy in a proof-of-concept clinical study. J. Antimicrob. Chemother. 77, 989\u2013995 (2022).","journal-title":"J. Antimicrob. Chemother."},{"key":"10662_CR20","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/s41577-022-00753-w","volume":"23","author":"BF Haynes","year":"2023","unstructured":"Haynes, B. F. et al. Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies. Nat. Rev. Immunol. 23, 142\u2013158 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"10662_CR21","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/imr.12484","volume":"275","author":"LE McCoy","year":"2017","unstructured":"McCoy, L. E. & Burton, D. R. Identification and specificity of broadly neutralizing antibodies against HIV. Immunol. Rev. 275, 11\u201320 (2017).","journal-title":"Immunol. Rev."},{"key":"10662_CR22","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1111\/imr.12506","volume":"275","author":"DM Margolis","year":"2017","unstructured":"Margolis, D. M., Koup, R. A. & Ferrari, G. HIV antibodies for treatment of HIV infection. Immunol. Rev. 275, 313\u2013323 (2017).","journal-title":"Immunol. Rev."},{"key":"10662_CR23","doi-asserted-by":"publisher","first-page":"595","DOI":"10.3390\/v5020595","volume":"5","author":"LA Araujo","year":"2013","unstructured":"Araujo, L. A. & Almeida, S. E. HIV-1 diversity in the envelope glycoproteins: implications for viral entry inhibition. Viruses 5, 595\u2013604 (2013).","journal-title":"Viruses"},{"key":"10662_CR24","doi-asserted-by":"publisher","first-page":"12921","DOI":"10.1128\/JVI.77.23.12921-12926.2003","volume":"77","author":"M Sagar","year":"2003","unstructured":"Sagar, M. et al. Infection with multiple human immunodeficiency virus type 1 variants is associated with faster disease progression. J. Virol. 77, 12921\u201312926 (2003).","journal-title":"J. Virol."},{"key":"10662_CR25","doi-asserted-by":"publisher","first-page":"6045","DOI":"10.1073\/pnas.0800159105","volume":"105","author":"AH Keeble","year":"2008","unstructured":"Keeble, A. H., Khan, Z., Forster, A. & James, L. C. TRIM21 is an IgG receptor that is structurally, thermodynamically, and kinetically conserved. Proc. Natl. Acad. Sci. USA 105, 6045\u20136050 (2008).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10662_CR26","doi-asserted-by":"publisher","first-page":"19985","DOI":"10.1073\/pnas.1014074107","volume":"107","author":"DL Mallery","year":"2010","unstructured":"Mallery, D. L. et al. Antibodies mediate intracellular immunity through tripartite motif-containing 21 (TRIM21). Proc. Natl. Acad. Sci. USA 107, 19985\u201319990 (2010).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10662_CR27","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1016\/j.cell.2017.10.033","volume":"171","author":"D Clift","year":"2017","unstructured":"Clift, D. et al. A method for the acute and rapid degradation of endogenous proteins. Cell 171, 1692\u20131706 e1618 (2017).","journal-title":"Cell"},{"key":"10662_CR28","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1021\/acsinfecdis.6b00189","volume":"3","author":"ER Gray","year":"2017","unstructured":"Gray, E. R. et al. Unravelling the molecular basis of high affinity nanobodies against HIV p24: in vitro functional, structural, and in silico insights. ACS Infect. Dis. 3, 479\u2013491 (2017).","journal-title":"ACS Infect. Dis."},{"key":"10662_CR29","doi-asserted-by":"publisher","first-page":"e0116878","DOI":"10.1371\/journal.pone.0116878","volume":"10","author":"R Haryadi","year":"2015","unstructured":"Haryadi, R. et al. Optimization of heavy chain and light chain signal peptides for high level expression of therapeutic antibodies in CHO cells. PLoS ONE 10, e0116878 (2015).","journal-title":"PLoS ONE"},{"key":"10662_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1401471","volume":"15","author":"J Reusch","year":"2024","unstructured":"Reusch, J. et al. TRIM21 and Fc-engineered antibodies: decoding its complex antibody binding mode with implications for viral neutralization. Front. Immunol. 15, 1401471 (2024).","journal-title":"Front. Immunol."},{"key":"10662_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42546-2","volume":"14","author":"A Fletcher","year":"2023","unstructured":"Fletcher, A. et al. A TRIM21-based bioPROTAC highlights the therapeutic benefit of HuR degradation. Nat. Commun. 14, 7093 (2023).","journal-title":"Nat. Commun."},{"key":"10662_CR32","doi-asserted-by":"publisher","unstructured":"Rossi, E., Meuser, M. E., Cunanan, C. J. & Cocklin, S. Structure, function, and interactions of the HIV-1 capsid protein. Life (Basel) https:\/\/doi.org\/10.3390\/life11020100 (2021).","DOI":"10.3390\/life11020100"},{"key":"10662_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s12977-021-00583-z","volume":"18","author":"WM McFadden","year":"2021","unstructured":"McFadden, W. M. et al. Rotten to the core: antivirals targeting the HIV-1 capsid core. Retrovirology 18, 41 (2021).","journal-title":"Retrovirology"},{"key":"10662_CR34","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.virol.2021.07.001","volume":"562","author":"A Alfadhli","year":"2021","unstructured":"Alfadhli, A. et al. Capsid-specific nanobody effects on HIV-1 assembly and infectivity. Virology 562, 19\u201328 (2021).","journal-title":"Virology"},{"key":"10662_CR35","doi-asserted-by":"publisher","unstructured":"Chen, G. et al. A promising intracellular protein-degradation strategy: TRIMbody-away technique based on nanobody fragment. Biomolecules https:\/\/doi.org\/10.3390\/biom11101512 (2021).","DOI":"10.3390\/biom11101512"},{"key":"10662_CR36","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s00430-009-0116-7","volume":"198","author":"J Wesolowski","year":"2009","unstructured":"Wesolowski, J. et al. Single domain antibodies: promising experimental and therapeutic tools in infection and immunity. Med. Microbiol. Immunol. 198, 157\u2013174 (2009).","journal-title":"Med. Microbiol. Immunol."},{"key":"10662_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-025-02270-4","volume":"23","author":"H Li","year":"2025","unstructured":"Li, H. et al. Nanobodies and their derivatives: pioneering the future of cancer immunotherapy. Cell Commun. Signal. 23, 271 (2025).","journal-title":"Cell Commun. Signal."},{"key":"10662_CR38","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/363446a0","volume":"363","author":"C Hamers-Casterman","year":"1993","unstructured":"Hamers-Casterman, C. et al. Naturally occurring antibodies devoid of light chains. Nature 363, 446\u2013448 (1993).","journal-title":"Nature"},{"key":"10662_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-024-02900-y","volume":"22","author":"E Alexander","year":"2024","unstructured":"Alexander, E. & Leong, K. W. Discovery of nanobodies: a comprehensive review of their applications and potential over the past five years. J. Nanobiotechnol. 22, 661 (2024).","journal-title":"J. Nanobiotechnol."},{"key":"10662_CR40","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.drudis.2016.04.003","volume":"21","author":"S Steeland","year":"2016","unstructured":"Steeland, S., Vandenbroucke, R. E. & Libert, C. Nanobodies as therapeutics: big opportunities for small antibodies. Drug Discov. Today 21, 1076\u20131113 (2016).","journal-title":"Drug Discov. Today"},{"key":"10662_CR41","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.pep.2016.03.004","volume":"123","author":"M Qasemi","year":"2016","unstructured":"Qasemi, M. et al. Construction and expression of an anti-VEGFR2 Nanobody-Fc fusionbody in NS0 host cell. Protein Expr. Purif. 123, 19\u201325 (2016).","journal-title":"Protein Expr. Purif."},{"key":"10662_CR42","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.bcp.2018.10.014","volume":"158","author":"V Bobkov","year":"2018","unstructured":"Bobkov, V. et al. Nanobody-Fc constructs targeting chemokine receptor CXCR4 potently inhibit signaling and CXCR4-mediated HIV-entry and induce antibody effector functions. Biochem. Pharm. 158, 413\u2013424 (2018).","journal-title":"Biochem. Pharm."},{"key":"10662_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.632687","volume":"12","author":"C Ackaert","year":"2021","unstructured":"Ackaert, C. et al. Immunogenicity risk profile of nanobodies. Front. Immunol. 12, 632687 (2021).","journal-title":"Front. Immunol."},{"key":"10662_CR44","doi-asserted-by":"publisher","first-page":"3273","DOI":"10.1074\/jbc.M806889200","volume":"284","author":"C Vincke","year":"2009","unstructured":"Vincke, C. et al. General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold. J. Biol. Chem. 284, 3273\u20133284 (2009).","journal-title":"J. Biol. Chem."},{"key":"10662_CR45","doi-asserted-by":"publisher","first-page":"e0145986","DOI":"10.1371\/journal.pone.0145986","volume":"11","author":"SA Ali","year":"2016","unstructured":"Ali, S. A. et al. A cell internalizing antibody targeting capsid protein (p24) inhibits the replication of HIV-1 in T cells lines and PBMCs: a proof of concept study. PLoS ONE 11, e0145986 (2016).","journal-title":"PLoS ONE"},{"key":"10662_CR46","doi-asserted-by":"publisher","unstructured":"Booiman, T., Jim\u00e9nez, V. C., van Dort, K. A., van\u2019t Wout, A. B. & Kootstra, N. A. Phosphodiesterase 8a supports HIV-1 replication in macrophages at the level of reverse transcription. PloS ONE https:\/\/doi.org\/10.1371\/journal.pone.0109673 (2014).","DOI":"10.1371\/journal.pone.0109673"},{"key":"10662_CR47","doi-asserted-by":"publisher","first-page":"7478","DOI":"10.1128\/jvi.71.10.7478-7487.1997","volume":"71","author":"A Bjorndal","year":"1997","unstructured":"Bjorndal, A. et al. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J. Virol. 71, 7478\u20137487 (1997).","journal-title":"J. Virol."},{"key":"10662_CR48","doi-asserted-by":"publisher","first-page":"6705","DOI":"10.1128\/jvi.69.11.6705-6711.1995","volume":"69","author":"J He","year":"1995","unstructured":"He, J. et al. Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. J. Virol. 69, 6705\u20136711 (1995).","journal-title":"J. Virol."},{"key":"10662_CR49","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1006\/viro.1995.1016","volume":"206","author":"RI Connor","year":"1995","unstructured":"Connor, R. I., Chen, B. K., Choe, S. & Landau, N. R. Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology 206, 935\u2013944 (1995).","journal-title":"Virology"},{"key":"10662_CR50","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/0042-6822(89)90521-7","volume":"171","author":"M Tersmette","year":"1989","unstructured":"Tersmette, M. et al. Detection and subtyping of Hiv-1 isolates with a panel of characterized monoclonal-antibodies to HIV P24gag. Virology 171, 149\u2013155 (1989).","journal-title":"Virology"},{"key":"10662_CR51","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1073\/pnas.0337541100","volume":"100","author":"NA Kootstra","year":"2003","unstructured":"Kootstra, N. A., Munk, C., Tonnu, N., Landau, N. R. & Verma, I. M. Abrogation of postentry restriction of HIV-1-based lentiviral vector transduction in simian cells. Proc. Natl. Acad. Sci. USA 100, 1298\u20131303 (2003).","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-10662-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-10662-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-10662-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:24:13Z","timestamp":1791350653000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-10662-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,13]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["10662"],"URL":"https:\/\/doi.org\/10.1038\/s42003-026-10662-6","relation":{},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,13]]},"assertion":[{"value":"11 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"1303"}}